The ECLIPSE Trials: Comparative Studies of Clevidipine to Nitroglycerin, Sodium Nitroprusside, and Nicardipine for Acute Hypertension Treatment in Cardiac Surgery Patients

医学 尼卡地平 心肌梗塞 麻醉 围手术期 硝普钠 冲程(发动机) 内科学 血压 心脏病学 机械工程 一氧化氮 工程类
作者
Solomon Aronson,Cornelius Dyke,Kevin A. Stierer,Jerrold H. Levy,Albert T. Cheung,Philip D. Lumb,Dean J. Kereiakes,Mark F. Newman
出处
期刊:Anesthesia & Analgesia [Lippincott Williams & Wilkins]
卷期号:107 (4): 1110-1121 被引量:234
标识
DOI:10.1213/ane.0b013e31818240db
摘要

BACKGROUND: Acute hypertension during cardiac surgery can be difficult to manage and may adversely affect patient outcomes. Clevidipine is a novel, rapidly acting dihydropyridine L-type calcium channel blocker with an ultrashort half-life that decreases arterial blood pressure (BP). The Evaluation of CLevidipine In the Perioperative Treatment of Hypertension Assessing Safety Events trial (ECLIPSE) was performed to compare the safety and efficacy of clevidipine (CLV) with nitroglycerin (NTG), sodium nitroprusside (SNP), and nicardipine (NIC) in the treatment of perioperative acute hypertension in patients undergoing cardiac surgery. METHODS: We analyzed data from three prospective, randomized, open-label, parallel comparison studies of CLV to NTG or SNP perioperatively, or NIC postoperatively in patients undergoing cardiac surgery at 61 medical centers. Of the 1964 patients enrolled, 1512 met postrandomization inclusion criteria of requiring acute treatment of hypertension based on clinical criteria. The patients were randomized 1:1 for each of the three parallel comparator treatment groups. The primary outcome was the incidence of death, myocardial infarction, stroke or renal dysfunction at 30 days. Adequacy and precision of BP control was evaluated and is reported as a secondary outcome. RESULTS: There was no difference in the incidence of myocardial infarction, stroke or renal dysfunction for CLV-treated patients compared with the other treatment groups. There was no difference in mortality rates between the CLV, NTG or NIC groups. Mortality was significantly higher, though, for SNP-treated patients compared with CLV-treated patients (P=0.04). CLV was more effective compared with NTG (P=0.0006) or SNP (P=0.003) in maintaining BP within the prespecified BP range. CLV was equivalent to NIC in keeping patients within a prespecified BP range; however, when BP range was narrowed, CLV was associated with fewer BP excursions beyond these BP limits compared with NIC. CONCLUSIONS: CLV is a safe and effective treatment for acute hypertension in patients undergoing cardiac surgery.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
朱朱发布了新的文献求助10
1秒前
1秒前
zz发布了新的文献求助10
1秒前
1秒前
萧澈完成签到,获得积分10
1秒前
ZIYUNI完成签到 ,获得积分10
3秒前
Cell完成签到 ,获得积分10
3秒前
3秒前
闪闪的小小完成签到 ,获得积分10
3秒前
4秒前
4秒前
小陈发布了新的文献求助10
5秒前
自由的觅松完成签到,获得积分10
5秒前
5秒前
5秒前
5秒前
超级的一鸣完成签到,获得积分10
5秒前
WYL发布了新的文献求助10
7秒前
zcs完成签到 ,获得积分10
7秒前
在水一方的应助被邻居家的猫采纳,获得10
7秒前
corleeang发布了新的文献求助10
8秒前
奥特曼完成签到,获得积分10
8秒前
又又完成签到,获得积分10
8秒前
xixidong发布了新的文献求助10
8秒前
8秒前
8秒前
9秒前
9秒前
星辰大海的应助被Firsterchao采纳,获得30
9秒前
故梦完成签到,获得积分20
9秒前
9秒前
dadada完成签到 ,获得积分10
10秒前
c29发布了新的文献求助10
10秒前
大与小房完成签到,获得积分10
11秒前
等待的含灵完成签到 ,获得积分10
11秒前
今后的应助被朱朱采纳,获得10
12秒前
12秒前
漫漫发布了新的文献求助10
12秒前
sttise完成签到 ,获得积分10
12秒前
run发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651